ArticleIBRO neuroscience reports2026
Association between dietary magnesium intake and epilepsy: The mediating role of composite dietary antioxidant index based on a cross-sectional study.
Article in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anti-Inflammatory and Antioxidant Strategies in Epilepsy: From Molecular Mechanisms to Threshold Management.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epilepsy affects 1.2 % of the US population, with one-third of cases being drug-resistant. Magnesium modulates neuronal excitability, and dietary insufficiency may elevate seizure risk. Systemic inflammation, quantified by the Composite Dietary Antioxidant Index (CDAI), represents a plausible mediator, but population-level evidence remains limited. Objective: To investigate associations between dietary magnesium intake and epilepsy prevalence, assess CDAI-mediated pathways, and identify high-benefit subgroups. Methods: Cross-sectional analysis included 33,486 adults (≥20 years) from NHANES 2013-2018. Dietary magnesium intake was derived from two 24-hour recalls and analyzed continuously (per SD) and categorically (quartiles). Epilepsy was self-reported. CDAI integrated six micronutrient intakes. Weighted multivariable logistic regression evaluated magnesium-epilepsy associations, adjusted for sociodemographic, clinical, and dietary covariates. Mediation analysis quantified CDAI's role. Results: After full adjustment, each SD increase in magnesium intake was associated with 62 % lower epilepsy prevalence (OR = 0.38, 95 % CI: 0.21-0.70, p = 0.004). Quartile analysis revealed a significant inverse trend (p-trend = 0.032), with Q4 (highest intake) exhibiting the lowest risk (OR = 0.38, 95 % CI: 0.12-1.15). CDAI mediated 50.1 % of magnesium's protective effect (indirect effect: -0.478, 95 % CI: -1.031 to -0.166; p < 0.001). Stronger inverse associations occurred in Non-Hispanic Black (OR = 0.32, 95 % CI: 0.11-0.94) and Mexican American (OR = 0.35, 95 % CI: 0.16-0.76) individuals (p-interaction = 0.009) and those with obesity (OR = 0.26, 95 % CI: 0.10-0.68). Conclusion: Higher dietary magnesium intake is associated with significantly reduced epilepsy prevalence in US adults, with half of this effect mediated by attenuated inflammation (CDAI). Populations with elevated inflammation burdens or socioeconomic disadvantages may derive particular benefit. These findings support magnesium-rich diets as a potential preventive strategy and warrant prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.